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Heterozygous Germline Mutations in the p53 Homolog
p63 Are the Cause of EEC Syndrome
in several EEC syndrome families to a region of chro-
mosome 3q27 previously implicated in the EEC-like
disorder, limb mammary syndrome (LMS). Analysis of
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Here we report the construction of a physical map
Summary from a 3 cM region containing the causative gene for
LMS. Linkage analysis revealed that the genetic defect
EEC syndrome is an autosomal dominant disorder in several EEC syndrome families colocalizes with the
characterized by ectrodactyly, ectodermal dysplasia, LMS locus. This observation suggested that these disor-
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ResultsTable 1. Linkage Analysis in Families with EEC Syndrome
Flanking Markers Linkage Analysis in EEC Families
Family Locus Zmax at u 5 0 (Proximal±Distal) To investigate the possibility of allelism with LMS, poly-
LMS D3S3530 12.01 D3S1580±D3S1314 morphic markers from the 3q27 region were used for
Ams-1 D3S3530 4.53 NDa±D3S1314 a linkage analysis in five families with EEC syndrome.
D19S49 4.06 D19S894±D19S416 Positive LOD scores were obtained with markers from
SLC-1 D3S3530 0.86 NDa
within the LMS interval for each of these families (TableSLC-2 D3S3530 1.76 NDa
1). The added Zmax across these families is 8.03 atBri-1 D3S1294 1.81 D3S3530±3qter
Leu-1 D3S3530 0.88 NDa marker D3S3530 at a recombination fraction u 5 0. Re-
combination events were observed between markersLinkage analysis in the EEC syndrome families was performed with
that define the LMS interval, D3S1580 and D3S1314,markers from the critical region that was defined previously for LMS
and the disease locus, indicating that these five EEC(van Bokhoven et al., 1999). Reconstructing haplotypes identified
flanking markers for the EEC syndrome families. Note that family syndrome families map to the same 3 cM region of
Ams-1 shows significant LOD scores for two loci. The chromosome 3q27 that was previously found for the LMS family (van
19 locus was found previously by O'Quinn et al. (1998). Bokhoven et al., 1999). This colocalization and the over-
a For these families no recombinations were detected in the region
lapping clinical features of these disorders strongly sug-around 3q27.
gest that the same gene is involved in both EEC and
LMS. If so, the critical region for EEC/LMS was reduced
to a 2.3 cM interval by a recombination event between
marker D3S3530 and the genetic defect in EEC family
al., 1998; Senoo et al., 1998; Trink et al., 1998; Yang et Bri-1 (64:1 odds).
al., 1998), a homolog of the archetypal tumor suppressor
gene p53, is abundantly expressed in proliferating basal
cells of epithelial layers in the epidermis (Yang et al., Physical Mapping of the LMS Critical Region
By using the Whitehead STS-based map of the human1998). In keeping with this expression pattern are the
phenotypes of the recently reported p63 knockout mice genome, YAC clones were selected that each should
contain several STSs from the region around D3S1580(Yang et al., 1999; Mills et al., 1999). p63-deficient mice
lack all squamous epithelia and their derivatives, includ- and D3S1314. The size and integrity of the YACs was
determined by pulsed field gel electrophoresis anding hair, whiskers, teeth, as well as the mammary, lacri-
mal, and salivary glands. Particularly striking are severe Southern blots probed with total human DNA (data not
shown). PCR was then performed to map STSs on thelimb truncations with forelimbs showing a complete ab-
sence of the phalanges and carpals, and variable de- YACs. This approach allowed us to place the YACs into
a contig covering the critical region for LMS/EEC syn-fects of ulnae and radiae and hindlimbs that are lacking
altogether. Subsequent analysis of the p63 gene re- drome (Figure 1). Five STSs within this region were de-
rived from expressed sequences (ESTs): A004N18, WI-vealed heterozygous mutations in nine unrelated pa-
tients with EEC syndrome. The p63 mutations act in a 6145, WI-19957, STSG1588, and SGC33716. According
to the Unigene database, each of these five ESTs repre-dominant fashion in humans, giving rise to a phenotype
that resembles that of p63 knockout mice. sents a cluster of 2 to 65 cDNA clones derived from
Figure 1. Physical Map of the Region Containing the Gene for EEC/LMS Syndrome
Genetic intervals for LMS and EEC syndrome are shown at top. The physical map underneath shows the approximate positions of genetic
markers, ESTs (indicated by asterisks), and the LPP and p63 genes. The order of genetic markers was deduced from genetic maps (Dib et
al., 1996), and confirmed by mapping of these markers to partially overlapping YAC clones from the 3q27 region. The vertical lines at the YAC
clones indicate the presence of a STS/EST as determined by PCR. YAC clones are from the CEPH megabase YAC library. Five ESTs map to the
LMS region and three map to the combined EEC/LMS region. The p63 gene is the only full-length cDNA that maps to the LMS/EEC critical region.
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Figure 2. Schematic Representation of the
Human p63 Gene and Position of Mutations
Found in EEC Syndrome Patients
(A) Intron±exon structure of the p63 gene
showing the two transcriptional start sites
and the various splicing events leading to the
6 known isotypes of p63 (Yang et al., 1998).
Initiation of transcription in exon 1 produces
the TA-isotypes, containing the transactiva-
tion (TA) domain, while initiation in exon 39
gives rise to the DN-isotypes without the TA
domain. The splicing events that produce the
a isotypes are indicated with solid lines; splic-
ing events that produce the b and g isotypes
are indicated with dotted lines. Protein do-
mains are shown for the TA-p63a and DN-p63g
isotypes. The open reading frame is indicated
in gray; conserved protein domains are high-
lighted with colors: red, transactivation do-
main; blue, DNA-binding domain; green,
isomerization domain. All missense muta-
tions are located in the DNA-binding domain,
which is contained in all 6 p63 isotypes. The
frameshift mutation [INS(A)] located in exon
13 is predicted to produce truncated a iso-
types, whereas the b and g isotypes are left
unaffected.
(B) Amino acid sequence comparison of the
DNA-binding domain of human p53, p63, and
p73. The highly conserved domains II to IV
that were identified by Cho et al. (1994) are
underlined. Blue shading depicts amino acids
that directly contact the DNA, and the red
colors indicate the Zn-binding amino acids.
The black bars indicate the relative frequency
of mutations that are found at a particular
amino acid of p53 from human tumor material
(Hollstein et al., 1991; Hainaut et al., 1998).
All amino acid substitutions that are found in
the p63 gene of EEC syndrome patients are
located in the conserved domains, and often
affect residues that bind to DNA or residues
that are frequently mutated in p53.
a variety of cDNA libraries. We checked by PCR the p63 Mutation Analysis
The p63 gene encodes multiple isotypes by two tran-localization of 5 known genes (LPP, Chordin, DVL3,
SOX2, and p63) on our YAC panel. Chordin, SOX2, and scription initiation sites and extensive alternative splic-
ing (Yang et al., 1998; Figure 2A). Since only the cDNADVL3 were negative for all YACs, whereas PCR frag-
ments of expected sizes were obtained in the reaction sequences of the human p63 gene were known, we set
out to resolve the genomic structure via an exon bridgingwith total human DNA. LPP was positive only for YAC
949G9, indicating that this gene is just outside the LMS/ technique. Exon-specific primers were designed based
on the proposed p63 gene structure (Yang et al., 1998).EEC critical region. However, it cannot be excluded that
part of the LPP gene or of its regulatory elements is By long-range PCR with YAC DNA as template, we were
able to amplify most of the introns of this gene (Figurewithin the LMS/EEC region. We therefore sequenced all
coding exons and flanking intron sequences of the LPP 2A). The splice sites and flanking intron sequences of the
PCR fragments were determined. These data allowed usgene in one LMS patient. Except for one intron polymor-
phism, no deviations from the reported sequences were to design intron-specific primers suitable for amplifica-
tion of exons 5 to 14. The resulting PCR fragments ob-detected. Finally, PCR amplification of part of exon 14
of the p63 gene revealed that this gene maps precisely tained from 25 unrelated EEC syndrome patients and a
patient from the LMS family were analyzed for mutationswithin the LMS critical region. This localization, in combi-
nation with the high expression level of p63 in epidermal by direct sequencing. A total of nine heterozygous
nucleotide changes were detected in EEC syndromecells and the phenotype of the recently reported p63
knockout mice (Yang et al., 1999; Mills et al., 1999), patients (Figure 2). The arginine at position 204 (number-
ing based on the TA-p63a isotype) was found to bemake this gene a likely candidate for LMS and EEC
syndrome. mutated in four unrelated patients, with three of these
Cell
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Figure 3. Segregation of p63 Mutations in
Families with EEC Syndrome
(A) Frameshift mutation in family Nij-4. Partial
sequence of a PCR amplicon containing exon
13 derived from patient Nij-1 (bottom) and her
healthy mother (top). The extra adenosine in
one of the alleles of the patient is not present
in her father's (not shown) and mother's DNA.
(B) ASO hybridization of the Arg279His muta-
tion in family SLC-1. PCR fragments derived
from exon 7 were electrophoresed in a 2%
agarose and transferred to two separate ny-
lon filters by Southern blotting. Each filter was
hybridized with a 32P-labeled oligonucleotide,
with either a complete match to the wild-type
allele (59-ATG AAC CGC CGT CCA ATT-39) or
to the mutant allele (59-ATG AAC CAC CGT
CCA ATT-39).
(C) Segregation of the Arg304Trp mutation in
family Nij-1. The 260 bp PCR fragment con-
taining exon 8 was digested with HpaII. The
wild-type product is cleaved into fragments
of 157 and 103 bp. Due to the mutation the
HpaII site is lost, resulting in partial digestion
of PCR fragments derived from affected indi-
viduals. Note that the mutation has occurred
de novo in the germline of one of the grand-
parents.
(D) Segregation of the Cys306Arg mutation in
family Nij-2. The 260 bp PCR fragment con-
taining exon 8 was digested with BamHI,
which gives rise to products of 155 and 105
bp for the mutant allele, while the wild-type
allele is not digested. Note that the mutation
has occurred de novo in the germline of one
of the parents.
showing a substitution by tryptophan and one by gluta- Protein Modeling Predicts an Impairment of DNA
Binding due to p63 Mutationsmine. In patient Nij-1 a change of C to T at nucleotide
position 910 (with respect to the A of the start codon) To obtain a structural context for the mutations de-
scribed here, we built a model of the p63 DNA-bindingresults in a missense mutation Arg304Trp. Another mis-
sense mutation Cys306Arg was found in patient Nij-2. domain based on the known structure of its homolog,
p53 (Chothia and Lesk, 1986; Sander and Schneider,Both mutations are located in exon 8 of the p63 gene,
which encodes a core element of the DNA-binding do- 1991; Cho et al., 1994; Chinea et al., 1995). According
to this model, the p53 and p63 DNA-binding domainsmain. Two other missense mutations, Ser272Asn and
Arg279His, are located in exon 7. Finally, an insertion assume a similar loop-sheet-helix motif and two large
loops that make up the DNA-binding surface of the pro-of one nucleotide (1572insA) was detected in exon 13
of patient Nij-4, resulting in a frameshift at codon 525 tein (Figure 4). This model is supported by the fact that
p53 and p63 bind to the same DNA motifs (Yang et al.,(tyrosine) and a premature stop codon in the same exon
(Figure 3A). 1998). All amino acids of p53 that directly contact the
DNA are conserved in p63, and therefore are predictedIn at least five families, the mutation is de novo: family
Nij-1 (Arg304Trp), Nij-2 (Cys306Arg), Nij-3 and Lei-1 to have similar functions (Figure 4). Three of the five
positions where amino acid changes cause EEC syn-(both Arg204Trp), and Nij-4 (frameshift) (Figure 3 and
data not shown). In two of the families that map to drome are directly implicated in DNA binding. The serine
at position 272 (241 in p53) makes a hydrogen bondchromosome 3q27, Leu-1 and SLC-1, cosegregation of
the mutation and the disease was observed (Figure 3B with a phosphate in the DNA backbone, which is lost
upon replacement of this residue by asparagine. Theand data not shown). For all mutations the mutant allele
was not present in 100 investigated control chromo- arginine at position 304 (273 in p53) contacts a backbone
phosphate. This contact is abrogated by the mutationsomes. A comparison between the DNA-binding do-
mains of p53, p63, and p73 demonstrated that all mu- to tryptophan, which in addition can impose steric hin-
drance on the DNA binding. Arginine 279 (248 in p53)tated amino acids are strictly conserved (Figure 2B).
These data confirm that the p63 sequence changes are reaches into the minor groove of the DNA where it con-
tacts nucleotides of adjacent pentamers of the consen-causative mutations for EEC syndrome.
We have not yet identified mutations in the LMS family sus sequence PuPuPuC(A/T) that is required for p53-
specific DNA recognition. The amino acid substitutionsnor in several EEC syndrome families mapping to 3q27.
Most likely, these mutations reside in other parts of at the two other positions, arginine 204 and cysteine
306, are predicted to diminish the DNA binding capacitythe p63 gene not analyzed here, including exons 1 to 4
or 15. of p63 through structural deformation of the protein.
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Figure 4. Modeling of the DNA-Binding Domain of p63
In all panels DNA is represented as a purple stick model. Protein is shown as a ribbon model with red strands, blue helices, and green turns
and loops. The side chains of interesting residues are shown as ball-and-stick models (C 5 green; N 5 blue; O 5 red; S 5 yellow; Zn 5
black).
(A) The protein±DNA complex viewed along the carboxy-terminal helix of the DNA-binding domain (Helix H2 in p53; Cho et al., 1994). From
left to right are shown Arg279 (248 in p53), Ser272 (241), and Arg304 (273).
(B) As in (A). Top to bottom are shown Arg311 (280), Asp312 (281), Cys306 (275), and Arg304 (273).
(C) Arg204 (175) is shown just below the Zn-binding site consisting of Cys205 (176), Cys269 (238), Cys273 (242), and His208 (179).
Cys306 (275 in p53) reaches inside the protein where p63 Mutations Affect Transactivation
and Dominant-Negative Propertiesit is located underneath the aspartate at position 312.
Asp312 plays an important role in the positioning of the To assess consequences of p63 mutations found in EEC
patients on p63 function, we performed transactivationp63 DNA-binding surface by forming salt bridges with
Arg304 and Arg311. The Cys306Arg mutation will disrupt assays with mutant p63 proteins, containing either an
amino acid substitution (Cys306Arg) or the frameshiftthe proper contacts between these two arginines and
the DNA by destabilizing the Asp312. In p53, the arginine mutation. Individual p63 mutant and control isotypes
were assayed in a cell transfection model for their ability(175) that corresponds to Arg204 in p63 has a critical
role in stabilizing two loops (L2 and L3; Cho et al., 1994). to transactivate p53 reporter genes and to suppress
p53- and p63-mediated transactivation, respectively.Cho et al. (1994) cite several lines of evidence that
suggest that mutations of this arginine lead to (partly) Whereas wild-type TA-p63g, like p53, is a potent trans-
activator of the p53-responsive reporter gene, the TA-unfolded protein. The high degree of local similarity
between p53 and p63 in this area of the molecule p63gCys306Arg mutant fails to drive expression from this
reporter gene (Figure 5A). The absence of transactiva-strongly suggests a similar role for Arg204 in p63, and
that mutation of this Arg to Trp or Gln will create exten- tion of the TA-p63gCys306Arg mutant might have been due
to trivial explanations such as destabilization or inabilitysive structural rearrangements. Thus, all missense mu-
tations are predicted to disrupt DNA binding either di- to access the nucleus. However, TA-p63gCys306Arg had a
similar nuclear localization as wild-type protein (datarectly by replacing amino acids that bind to DNA, or
indirectly by creating marked changes in the structural not shown), suggesting the more likely possibility that
the Cys306Arg mutation affects p63 binding to DNA
Cell
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Figure 5. Transactivation of a p53 Reporter
Gene by Wild-Type and Mutant p53 and p63
Isotypes
(A) Human Saos-2 cells were transfected as
indicated, lysed in detergent lysis buffer
24±36 hr after transfection, and assayed for
transactivation using a b-galactosidase re-
porter gene containing p53-binding sites
(PG13-b-gal). The transactivation activity of
TA-p63g is lost due to the Cys306Arg mu-
tation.
(B) Transactivation analysis in Saos-2 cells
transfected with wild-type p53 expression
vector, minimal p53 reporter construct, and
either wild-type (WT) or mutant (M) expres-
sion vectors at a 1:1 ratio with respect to p53,
as indicated.
(C) As in (B) except that TA-p63g instead of
p53 expression vector was used.
(D) Assessment of the consequences of
the frameshift mutation (TA-p63aFS and
DN-p63aFS) for transactivation. Assays were
conducted with the indicated combination of
constructs as in the above panels.
A constitutive luciferase expression vector
(PGL3; Promega) was used in all samples to
normalize for transfection efficiency and
sample preparation. Error bars indicate SD in
triplicate experiments. The relative transacti-
vation at the vertical axis is the degree of
stimulation with respect to assays with vector
without p53/p63 sequences.
target sites. DN-p63a, the major p63 isotype in basal cells the formation of defective heterooligomers between TA-
p63g and DN-p63aCys306Arg. The formation of defective het-of epithelial tissues (Yang et al., 1998), lacks transactiva-
tion capabilities against p53 reporter genes but rather erooligomeric complexes is also suggested by the effect
of mutant DN-p63g toward TA-p63g transactivation.shows remarkable dominant-negative activities toward
transactivation of these genes by both p53 and TA-p63g Whereas wild-type DN-p63g slightly stimulates rather
than suppresses transactivation by TA-p63g, repression(Yang et al., 1998). We asked whether the Cys306Arg
substitution in DN-p63a would affect these dominant- of transactivation is brought about by DN-p63gCys306Arg.
It is likely that the ability of heterooligomer formationnegative activities toward p53 and TA-p63g in the trans-
fected cell model. As expected, wild-type DN-p63a between mutant and wild-type p63 isotypes underlies
the dominant nature of the p63 missense mutations instrongly repressed p53-induced transactivation of the
p53 reporter gene (Figure 5B), which is likely attributed EEC syndrome.
We next investigated whether the frameshift mutationto effective competition for p53 DNA target sequences
(Yang et al., 1998). In contrast, coexpression of the had similar trans-dominant effects on transactivation.
While TA-p63a normally lacks transactivation activity,DN-p63aCys306Arg mutant showed no significant effect on
the transactivation activity of p53 (Figure 5B), which indi- its truncated derivative, TA-p63aFS, is a strong activator
of reporter gene expression (Figure 5D). Thus, the TA-cates that the mutation disrupts the DNA-binding ability
of this p63 isotype. Similar effects toward p53 transactiva- p63aFS mutant has not only maintained its DNA binding
capacity but has also acquired transactivation activitytion were observed for wild-type and mutant DN-p63g
isotype (Figure 5B). The effects of DN-p63aCys306Arg ex- compared to TA-p63a. TA-p63aFS lacks almost half of
the carboxy-terminal a tail of TA-p63a, which is com-pression on the transactivation functions of TA-p63g in
this cell model were more complex than toward p53. pletely absent in TA-p63g. Apparently, the a tail, or more
specifically the domain that is encoded downstream ofDN-p63aCys306Arg was as effective as wild-type DN-p63a
in blocking transactivation by TA-p63g (Figure 5C). Since the nucleotide insertion, confers an autoinhibitory effect
on p63 transactivation. We then asked how the trunca-DN-p63aCys306Arg does not seem to have DNA binding ca-
pacity, the observed suppression is likely the result of tion of the a tail would affect the suppressive activities
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toward p53 and TA-p63g transactivation. In the cotrans- somatic mutations seen in tumors. The p63 mutations
found in the EEC patients occur at amino acids thatfection assays, DN-p63aFS suppressed p53-mediated
transactivation, which reflects the retained DNA binding are commonly altered in p53 proteins found in human
malignancies (Hollstein et al., 1991; Hainaut et al., 1998;capacity of this mutant isotype. Cotransfection of
DN-p63aFS with either TA-p63g or TA-p63aFS, however, Walker et al., 1999). There is evidence that the high
incidence of mutations at these amino acids in p53 isyielded a significantly higher reporter gene expression
than in the absence of DN-p63aFS (Figure 5D). Appar- due to a combination of diverse environmental muta-
gens, that preferentially bind to CpG dinucleotides, andently, DN-p63aFS is able to form potent transactivation
complexes with the TA-p63 isoforms. A similar, but less strong positive selection for mutations, especially for
those in the DNA-binding domain (Sidransky et al., 1992).pronounced activity was observed for wild-type DN-
p63g in such cotransfection assays (Figures 5B and 5C). A similar mechanism of positive selection for muta-
tions seems unlikely for p63. Examination of the nucleo-
tide changes in the p63 gene reveals that six of nineDiscussion
mutations are C-to-T transversions at CpG dinucleo-
tides either on the coding (Arg204Trp [3x], Arg304Trp)p63 Mutations Cause EEC Syndrome
or on the noncoding strand (Arg204Gln, Arg279His). ItWe have demonstrated that mutations in p63 are an
thus seems possible that the codons for these aminoimportant cause of the EEC syndrome. p63 mutations
acids are hot spots for mutations. An alternative expla-were found in nine unrelated families. Eight of these
nation would be that mutation of specific residues suchmutations cause amino acid substitutions. The ninth
as Arg204 leads to the characteristic ectodermal andmutation introduces a frameshift in exon 13 of the p63
limb abnormalities seen in EEC syndrome, whereas mu-gene, and causes a premature termination codon in the
tations at other positions could lead to a different pheno-same exon. Unequivocal evidence that the mutations
type or have no consequences at all. Despite the aminoare causative for EEC syndrome was provided by the
acid homology between p53 and p63, and the ability ofobservation that the changes are de novo in five of
p63 to transactivate p53 target genes (Shimada et al.,the families. In addition, the missense mutations are
1999), there is no indication for an increased susceptibil-predicted to affect the DNA binding capacity of p63,
ity for cancer development in EEC syndrome patients.which results in impaired transactivation activity and
Further studies in larger numbers of patients and fami-altered regulation of transactivation. The premature stop
lies with EEC and EEC-like phenotypes (such as LMS)codon introduced by the frameshift mutation does not
may clarify these issues and, eventually, may enable theaffect the b and g isotypes of p63, suggesting a major
identification of genotype±phenotype correlations.role for mutant p63a isotype(s) in the pathogenesis of
EEC syndrome. After screening 10 exons (5 to 14) of the
p63 gene, we have detected mutations in nine of 25
p63 Missense Mutations Affect DNA Bindingfamilies, indicating that mutations in the p63 gene are
The p63 structure model indicates that the observeda major cause of EEC syndrome.
mutations in EEC syndrome patients will partially orThe localization of the genetic defect in EEC syndrome
completely abolish DNA binding, either because thefamily Ams-1 to the 3q27 region was unexpected, be-
DNA contacting amino acids are mutated or because ofcause in a previous study significant support was ob-
disruption of the structural integrity of the DNA-bindingtained for a location on chromosome 19 (Table 1;
surface. As a consequence of the diminished DNA bind-O'Quinn et al., 1998). It is possible that the linkage de-
ing, the transactivation capacity of the mutant proteintected at one of these loci is spurious. Alternatively, the
will also be reduced. Indeed, cell lysates containing theidentification of linkage to two loci may be indicative
TA-p63g isotype with the Cys306Arg mutation showedfor the involvement of genes from the corresponding
a total lack of transactivation activity, whereas lysateschromosomal regions acting in concert in develop-
with the normal TA-p63g isotype do activate transcrip-mental processes that are disturbed in this family. A
tion of a b-gal reporter gene under control of a minimalgene from chromosome 19 may thus act as a modifier
p53-binding site. Additional evidence that the Cys306Arggene by modulating the phenotypic outcome of p63
mutation results in a loss of DNA binding capacity ismutations.
provided by the observation that the DN-p63aCys306Arg mu-
tant isotype is unable to suppress p53-mediated trans-p63 Mutations in EEC Syndrome Correspond to p53
activation, whereas wild-type DN-p63a efficiently com-Hot Spot Mutations in Human Tumors
petes with p53 for DNA target sites. The frameshiftAll of the p63 missense mutations in EEC syndrome
mutation does not have any apparent effect on the DNApatients affect the core DNA-binding domain of the pro-
binding capacity of p63, but the resulting truncation oftein at amino acid residues that are strictly conserved
the carboxy-terminal domain clearly has an effect onamong the other members of the p53 family (Figure 2;
the normal transactivation (see below).Kaghad et al., 1997; Schmale and Bamberger, 1997;
Yang et al., 1998). Within this DNA-binding domain four
evolutionary conserved regions can be distinguished,
The Dominant Nature of p63 Mutationsdenoted regions II to V, which are critically important
Both EEC syndrome and LMS are inherited in a dominantfor the proper folding of the protein and for creation of
fashion. Since most mutations identified here in EECthe DNA-binding surface (Cho et al., 1994). All of the
syndrome are predicted to lead to amino acid substitu-identified p63 missense mutations are located in regions
III, IV, and V, which in p53 harbor the vast majority of tions, several pathogenic mechanisms are possible. It
Cell
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Figure 6. Limb Defects in EEC Syndrome Pa-
tients with a Mutation in p63
Typical split-hand with dystrophic nails of the
thumbs (A) and typical split-feet (B) from the
EEC syndrome patient with a frameshift mu-
tation in exon 13. (C) Cutaneous syndactyly
of second and third fingers of the right hand
and (D) partial syndactyly of the third and
fourth toes of the left foot of the girl with the
Arg304Trp mutation (family Nij-1).
cannot be concluded yet which mechanism, haploinsuf- toward TA-p63g, with which complex formation is possi-
ble, while it has retained its suppressive effect on p53-ficiency, dominant-negative, or gain of function, is appli-
cable. Also, the full constellation of symptoms observed mediated transactivation.
in EEC syndrome might be caused by a combination of
these mechanisms, as was previously found for several
Causal Heterogeneity of Mechanisms Leading
p53 mutations in human tumors (for reviews see Zam-
to EEC Syndrome
betti and Levine, 1993; Ko and Prives, 1996; Levine,
An inherent consequence of the gene structure of p63
1997). The existence of different p63 isotypes with differ-
is that the mutations observed will affect the function
ent properties may complicate the effect of mutations
of multiple p63 isotypes. The missense mutations are
even more.
predicted to affect all six known p63 isotypes, resulting
We feel, however, that haploinsufficiency is not a likely
both in a loss of transactivation by TA-p63g and to a
explanation, because patients with germline deletions
disruption of repressive properties of other isotypes to-
of chromosome 3q27-qter lack the defining features of
ward TA-p63g. The frameshift mutation, which was
EEC/LMS (Chitayat et al., 1996 and references therein).
found in a patient with a typical EEC syndrome, should
In addition, the p63 homozygous knockout mice that
not interfere with the production of either the p63g or
were recently created have severe ectodermal defects
p63b variants. Consequently, EEC syndrome is not due
and limb anomalies which recall most of the characteris-
to a loss of p63 transactivation per se, since the trans-
tics of EEC/LMS, but heterozygous wt/2 mice have no
activating isotype (TA-p63g) is left intact. Instead, the
obvious phenotypic abnormalities (Mills et al., 1999;
frameshift mutation results in a gain of transactivation
Yang et al., 1999). It thus seems that the human p63
activity for the truncated TA-p63a isotype. The missense
mutant proteins found in EEC syndrome exert a domi-
and frameshift mutations appear to exhibit divergent
nant-negative or a gain-of-function effect. The acquired
effects on the regulation of transcriptional activity of
transactivation activity of TA-p63a with the carboxy-
p63 as well. The Cys306Arg missense mutation sup-
terminal truncation could be a gain of function (Figure
presses the p63-mediated transactivation, whereas the
5D). However, due to the ability of p63 isotypes to form
frameshift mutation has a stimulatory effect. The above
homo- and heterooligomeric complexes, this mutation,
data suggest that both an increase and a decrease of
like the Cys306Arg mutation, also has dominant-nega-
transactivation by p63 lead to the developmental de-
tive properties in other transactivation assays. Hetero-
fects seen in EEC syndrome patients. Of course, this
oligomeric complex formation underlies the normal sup-
observation is based on transactivation studies with a
pressive and slightly stimulatory activities of the DN-p63a
target gene under control of a p53 response element.
and DN-p63g isotypes, respectively, toward TA-p63g
The effects in vivo on the transcriptional regulation of
transactivation (Figure 5C; Yang et al., 1998). Incorpora-
the normal p63 target genes may be dependent on addi-
tion of mutant isotypes may alter the properties of the
tional factors such as the DNA-binding sequence and
entire complex. Indeed, the existence of such com-
the nuclear environment.
promised complexes is suggested by our finding that
mutant DN-p63gCys306Arg has repressive effects toward
TA-p63g transactivation. DN-p63gCys306Arg has no effect The EEC Phenotype Resembles that of p63
Knockout Micetoward transactivation by p53, with which it is unable
to complex (Figure 5). Likewise, the normal repressive A comparison of the phenotype of p632/2 mice with that
of patients who have EEC syndrome shows a strikinglyactivity of DN-p63a is converted into a stimulatory effect
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was measured by optical density (OD260) and purity checked bysimilar pattern of involved structures. A generalized ec-
determining the OD260/OD280 ratio. Manual genotyping of microsatel-todermal dysplasia is evident in these patients, which
lite markers from chromosome 3q27 was carried out as describedmanifests as sparse hair, dry skin, pilosebaceous gland
elsewhere (Kremer et al. 1994). Two-point LOD scores were calcu-
dysplasia, lacrimal duct obstruction, and oligodontia. lated by the LINKAGE package (Lathrop and Lalouel, 1984). Pene-
Cleft lip with or without cleft palate occurs in the majority trance was arbitrarily determined at 95% and marker-allele frequen-
cies were estimated by use of the ILINK option. Disease-geneof EEC syndrome patients, which compares to the trun-
frequency was defined at 0.0001.cated secondary palate and hypoplastic maxilla and
mandibula in p632/2 mice (Mills et al., 1999; Yang et al.,
Physical Map Construction and Localization1999). There is a wide variety of abnormalities of hand
of Genes and ESTsand feet, ranging from syndactyly to a severe defect of
YAC clones from the critical region for LMS/EEC syndrome were
the central rays leading to a split hand/split foot malfor- selected by using the publicly available resources of the physical
mation (Figure 6). It has been proposed that during evo- mapping project of the Whitehead Institute (http://www-genome.
wi.mit.edu/; Dib et al., 1996). Yeast cell culturing and DNA isolationlution similar molecular signaling pathways have been
was performed as described previously (Green and Olson, 1990).recruited for the formation of structures as diverse as
STS markers, ESTs, and genes were physically mapped to theselimbs, hair, teeth, and apocrine glands (Thesleff et al.,
YACs by PCR. Sequences of primers used for mapping of ESTs and1995). How these different developmental programs are
genes are available upon request.
regulated is largely unknown, but it is of interest that all
these structures are affected by heterozygous muta- Elucidation of the Intron±Exon Boundaries
tions of p63. What these structures have in common is of the p63 Gene
Primer pairs that were predicted to match neighboring exons of thethat their development and morphogenesis depends on
human p63 gene were used to amplify the intervening intron fromthe signaling between specialized ectodermal cells and
YAC clone 745A12 or total human genomic DNA. Reactions werethe underlying mesoderm. Epithelial±mesenchymal in-
carried out in a 50 ml volume containing 20 mM Tris-HCl (pH 8.4),teractions between the apical ectodermal ridge (AER)
50 mM KCl, 1.5 mM MgCl2, 1 mM dNTPs, 250 ng of each primer,and the underlying mesenchyme, denoted the progress and 1.25 unit ExTaq (TaKaRa Biomedicals) under the following con-
zone, are required for normal morphogenesis of the limb ditions: 1 min 948C, 30 cycles consisting of 5 min 988C, 30 s 508C
and 15 min 688C, and 10 min 728C. PCR products were fractionated(Niswander, 1997). Indeed, the limb truncations in p632/2
by electrophoresis in 2% agarose gels and visualized by stainingmice seem to be the result of a failure to maintain the
with ethidium bromide. DNA fragments were excised from the gelAER (Yang et al., 1999).
and purified with the Qiaquick gel extraction protocol (Qiagen). Se-Clinical variability is one of the hallmarks of EEC syn-
quencing of these fragments was done with the BigDye Terminator
drome, with clinical expression ranging from severe dis- chemistry (PE Applied Biosystems) and the use of exon-specific
tal truncations in split hand/split foot malformation primers. Electrophoresis and analysis was performed on an ABI
Prism 377 (PE Applied Biosystems). In case the above exon-bridging(SHFM) to nonpenetrance in obligate heterozygotes who
strategy was unsuccessful, exon±intron boundaries were deter-are clinically normal. There are several possible explana-
mined by direct sequencing with exon-specific primers and PACtions for this extreme variability of symptoms in EEC
DNA as template.syndrome. First, stochastic processes may underlie the
severity of the various defects. The complexity of inter-
p63 Mutation Analysis
actions between mutant and wild-type isotypes of p63 Intron-specific primers were designed that are suitable for amplifica-
could certainly account for this. Secondly, the extent of tion of exons 5 to 14 of the p63 gene: 5F: 59-GTT GGT TCT CTC
CTT CCT TTC-39; 5R: 59-GCC CAC AGA ATC TTG ACC TTC-39; 6F:the defects may be determined by the action of modifier
59-CCA CCA ACA TCC TGT TCA TGC-39; 6R: GTT CTC TCA AGTgenes and/or environmental factors. A precedent for
CTA CTC AGT CC-39; 7F: 59-GGG AAG AAC TGA GAA GGA ACAmodifier genes is provided by the Dactylaplasia (Dac)
AC-39; 7R: 59-CAG CCA CGA TTT CAC TTT GCC-39; 8F: 59-GTA GATmouse mutant, which is considered a model for human
CTT CAG GGG ACT TTC-39; 8R: 59-CCA ACA TCA GGA GAA GGA
SHFM3. The Dac mouse shows central ray defects of TTC-39; 9F: 59-ATG CAT TAG TGC TTT AGA AGT G-39; 9R: 59-GAA
the forelimbs due to excessive cell death of the AER GGT TAA AAT GAA GCA ACC-39; 10F: 59-TGA GGA TTG ACC ACA
CTT CTA AC-39; 10R: 59-CAT CAA TCA CCC TAT TGC TGA TC-39;(Seto et al., 1997). The severity of the limb defects in
11F: 59-TGA NCA TCA TTT CCA TGT TTG TC-39; 11R: 59-TCA CAGDac1/2 mice is dependent on a recessive mutation in a
AGT CTT GTC CTA AGC-39; 12F: 59-CAA GAT GGA CCA CTG GGAmodifier gene, denoted mdac (Johnson et al., 1995).
TG-39; 12R: 59-GGA CTA TAA CAG TAT CCG CCC-39; 13F: 59-CTTBy analogy, the various SHFM loci and other unknown
ATC TCG CCA ATG CAG TTG G-39; 13R: 59-AAC TAC AAG GCG
genes may act as modifiers of phenotypic expression GTT GTC ATC AG-39; 14F: 59-GGG AAT GAT AGG ATG CTG TGG-
in EEC/LMS patients. This notion is supported by the 39; 14R: 59-AAG ATT AAG CAG GAG TGC TT-39. PCR reactions were
carried out in a 25 ml volume containing 100 ng genomic DNA, 20possible involvement of two loci, p63 and a locus on
mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs,chromosome 19, in one of the EEC families (O'Quinn et
100 ng of each primer, and 1 unit Taq polymerase (GIBCO-BRL),al., 1998 and this report). The hypothesis of specific
using the following parameters: 1 min 948C, 2 min 558C, 1 min 728Cmodifier genes can be further pursued by molecular
for 35 cycles. The resulting PCR products were directly sequenced
studies of large families with a single p63 mutation such as described above.
as the LMS family reported earlier (van Bokhoven et al., Sequence alterations were checked in the families of the corre-
sponding patient and in 50 control individuals by allele-specific oli-1999).
gonucleotide (ASO) hybridization or restriction enzyme digestion
of PCR products from the relevant exons. ASO hybridization andExperimental Procedures
washing was performed as described by Shuber et al. (1993).
Linkage Analysis
After obtaining informed consent, genomic DNA from EEC syndrome p63 Protein Modeling
A model of the DNA binding domain of p63 was created by usingfamilies was extracted from peripheral blood lymphocytes by a salt
extraction procedure (Miller et al. 1988). The DNA concentration the modeling methods described by Chinea et al. (1995) and the
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resolved structure of p53 as template (Cho et al., 1994). Sequence artificial chromosome libraries by use of the polymerase chain reac-
tion. Proc. Natl. Acad. Sci. USA 87, 1213±1217.alignment and homology modeling were done with the program
WHAT IF (Vriend, 1990). Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flo-
res, T., Hollstein, M., Harris, C.C., and Montesano, R. (1998). IARC
database of p53 gene mutations in human tumors and cell lines:Transactivation Assays
updated compilation, revised formats and new visualisation tools.Plasmid DNA from mammalian expression vectors containing the
Nucleic Acids Res. 26, 205±213.murine p63 sequence under control of a CMV promoter (Yang et
al., 1998) was used as template for site-directed mutagenesis using Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991).
p53 mutations in human cancers. Science 253, 49±53.the QuikChange procedure (Stratagene). To create the Cys306Arg
mutation we used oligonucleotide 59-TCC TGG GCA AGC ACG GAT Johnson, K.R., Lane, P.W., Ward-Bailey, P., and Davisson, M.T.
CCG GGC CTC AA-39 and the reverse complement of it. For con- (1995). Mapping the mouse Dactylaplasia mutation, Dac, and a gene
struction of the frameshift mutation we employed oligonucleotide that controls its expression, mdac. Genomics 29, 457±464.
59-CAT CAT GTC TGG ACA TAT TTC ACG ACC CA-39 and its reverse Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent,
complement. Clones containing the Cys306Arg mutation were se- A., Minty, A., Chalon, P., Lelias, J.M., Dumont, X., et al. (1997).
lected for by digestion with BamHI, for which a recognition site was Monoallelically expressed gene related to p53 at 1p36, a region
created by the mutation. The entire open reading frame of each frequently deleted in neuroblastoma and other human cancers. Cell
clone was checked by sequencing. Transactivation assays were 90, 809±819.
conducted as described previously (Yang et al., 1998).
Ko, L.J., and Prives, C. (1996). p53: puzzle and paradigm. Genes
Dev. 10, 1054±1072.
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